Is 2014 a Game Changer for the 340B Drug Discount Program

    As reported in Health Law and Policy Matters

    January 31, 2014

    (1/29, Ellyn L. Sternfield, Health Law & Policy Matters) reports “…The year 2014 looks to be a year of major developments for the 340B Drug Discount Program. We have seen (1) a first in terms of the Health Resources and Services Administration (HRSA) imposing sanctions on audited entities, (2) written arguments in a lawsuit over the rules governing 340B access to orphan drugs, and (3) increased funding for HRSA oversight through the recently-passed Omnibus Budget Act. But it is HRSA’s planned publication of regulations in June that may have the greatest impact on 340B Program operations.”

    View details